Analysis for CLX

$86.20 +1.23 (+1.45%)

📈 Growth — 6/30
💰 Profitability — 14/20
🏦 Financial Health — 12/20
💵 Valuation — 10/20
⚠️ Risk — 7/10

Overall Score: 45/100

Summary:

📈 Growth & Financial Trajectory

Across the 7 available quarters (partial view of an 8-quarter cycle), CLX's Revenues ranged roughly $1.66B–$1.79B with a notable spike in 2025 Q4. Net income fluctuated from about $80M to $336M, yielding a modest growth path that ends below the early-quarter level. The late-2025 period shows the strongest profitability, while 2026 data hint at a softer start before a later rebound. Overall, revenue trended flat to down slightly from start to end.

💰 Margins & Cash Flow

Gross margin stayed solid, about 41%–51%, with better leverage in the strongest quarters. Operating leverage appears moderate; SG&A and benefits costs run as a sizable fixed share of revenue. Net cash flow from operating activities remained positive, typically in the $180–$311M range, while investing cash flow was modestly negative and financing activity cash flows were volatile, producing uneven free cash flow.

🛡️ Balance Sheet & Liquidity

Total assets sit around $5.5–7.8B, with liabilities broadly in line (~$5.3–5.6B). Equity to the parent has been variable and sometimes negative, and long‑term debt has been elevated (roughly $2.5–4.0B). Despite this, operating cash flow supports liquidity, aided by noncontrolling interest in several periods.